Agent Description
Ensartinib is a small molecule, ALK inhibitor that potently inhibits ALK and most of its alternations (fusions, mutants). It is also a potent EphA2 inhibitor with modest selectivity with respective to other Ephrin isoforms. It is orally bioavailable and supplied in capsules.
Mechanism of Action
Inhibition of ALK, whose aberration causes cancers
Classification
ALK inhibitor
Molecular Target
ALK, TrkA, TrkC, ROS, EphA2, c-MET
Monograph
Ensartinib has shown very good efficacy in ALK positive non-small cell lung cancer (NSCLC) patients whose cancer progressed on crizotinib in the Phase 1/2 trial. Currently, it is in Phase 3 trial comparing to crizotinib in patients with ALK-positive NSCLC.
Studies of Interest
New indications as an ALK inhibitor, EphA2 inhibitor. Combination studies.
Information collaborator would like included in investigator proposals
N/A